Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Cash & Current Investments (2017 - 2025)

Inspire Medical Systems (INSP) has disclosed Cash & Current Investments for 9 consecutive years, with $308.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 30.81% to $308.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $308.3 million through Dec 2025, down 30.81% year-over-year, with the annual reading at $308.3 million for FY2025, 30.81% down from the prior year.
  • Cash & Current Investments hit $308.3 million in Q4 2025 for Inspire Medical Systems, down from $322.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $467.1 million in Q2 2023 to a low of $196.3 million in Q2 2022.
  • Historically, Cash & Current Investments has averaged $351.0 million across 5 years, with a median of $390.1 million in 2024.
  • Biggest five-year swings in Cash & Current Investments: surged 137.9% in 2023 and later plummeted 31.56% in 2025.
  • Year by year, Cash & Current Investments stood at $214.5 million in 2021, then skyrocketed by 110.48% to $451.4 million in 2022, then rose by 1.99% to $460.4 million in 2023, then dropped by 3.22% to $445.5 million in 2024, then tumbled by 30.81% to $308.3 million in 2025.
  • Business Quant data shows Cash & Current Investments for INSP at $308.3 million in Q4 2025, $322.6 million in Q3 2025, and $300.9 million in Q2 2025.